본문 바로가기
KERD
논문KCI 등재

한국인과 코카시안 충수돌기염 환자에서 비모수적 기대최대치(NPEM) 연산방법에 의한 겐타마이신의 모집단 약물동태학

Population Pharmacokinetics for Gentamicin in Korean and Caucasian Appendicitis Patients Using Nonparametric Expected Maximum (NPEM) Algorithm

범진필
한국임상약학회 (Korean College Of Clinical Pharmacy)|2011.07|한국임상약학회지 (Korean Journal of Clinical Pharmacy)|제21권 제2호|pp. 74-80

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

KoreanpopulationpharmacokineticsCaucasiangentamicinNPEM
주제분류약학

초록

Population pharmacokinetics for gentamicin were compared with 20 Korean patients (14 male and 6 female) and 25Caucasian appendicitis patients (16 male and 9 female). Two to six blood specimens were collected from all patients at the following times : just before a regularly scheduled infusion and at 0.5 hour after the end of a 0.5 hour infusion. Nonparametric expected maximum(NPEM) algorithm for population modeling was used. The estimated parameters were the elimination rate constant(K), the slope(KS) of the relationship between K versus creatinine clearance(Ccr), the apparent volume of distribution (V), the slope(VS) of the relationship between V versus weight, gentamicin clearance(CL) and the slope(CS) of the relationship between CL versus Ccr and the V. The output includes two marginal probability density function(PDF), means, medians, modes, variance, skewness, kurtosis, and CV%. The mean K(KS)were 0.402±0.129 hr^(-1) (0.00486±0.00197 [hr·mL/min/1.73 m²]^(-1) and 0.425±0.137 hr^(-1)(0.00432±0.00168 [hr·mL/min/1.73 m²]^(-1)for Korean and Caucasian populations, respectively. The mean V(VS) were not different at 14.3±3.69 L(0.241±0.0511 L/kg) and 15.8±4.81 L (0.236±0.0531 L/kg) for Korean and Caucasian populations, respectively (P>0.2). The mean CL(CS) were 5.68±1.69 L/hr (0.0714±0.0222 L/kg[hr·mL/min/1.73 m²]) and 6.29±1.84 L/hr (0.0629±0.0189 L/kg[hr·mL/min/1.73 m²]) for Korean and Caucasian populations, respectively. There are no differences in gentamicin pharmacokinetics between Korean and Caucasian appendicitis patients.

Abstract

Population pharmacokinetics for gentamicin were compared with 20 Korean patients (14 male and 6 female) and 25Caucasian appendicitis patients (16 male and 9 female). Two to six blood specimens were collected from all patients at the following times : just before a regularly scheduled infusion and at 0.5 hour after the end of a 0.5 hour infusion. Nonparametric expected maximum(NPEM) algorithm for population modeling was used. The estimated parameters were the elimination rate constant(K), the slope(KS) of the relationship between K versus creatinine clearance(Ccr), the apparent volume of distribution (V), the slope(VS) of the relationship between V versus weight, gentamicin clearance(CL) and the slope(CS) of the relationship between CL versus Ccr and the V. The output includes two marginal probability density function(PDF), means, medians, modes, variance, skewness, kurtosis, and CV%. The mean K(KS)were 0.402±0.129 hr^(-1) (0.00486±0.00197 [hr·mL/min/1.73 m²]^(-1) and 0.425±0.137 hr^(-1)(0.00432±0.00168 [hr·mL/min/1.73 m²]^(-1)for Korean and Caucasian populations, respectively. The mean V(VS) were not different at 14.3±3.69 L(0.241±0.0511 L/kg) and 15.8±4.81 L (0.236±0.0531 L/kg) for Korean and Caucasian populations, respectively (P>0.2). The mean CL(CS) were 5.68±1.69 L/hr (0.0714±0.0222 L/kg[hr·mL/min/1.73 m²]) and 6.29±1.84 L/hr (0.0629±0.0189 L/kg[hr·mL/min/1.73 m²]) for Korean and Caucasian populations, respectively. There are no differences in gentamicin pharmacokinetics between Korean and Caucasian appendicitis patients.

참고문헌 (34)

  1. Sheiner BB, "Forecasting individual pharmacokinetics", Clin Pharmac Ther, 31, pp.294~299 (1979)
  2. Hurst A, "Application of a bayesian method to monitor and adjust vancomycin dosage regimens", Antimicrob Agents Chemother, 34, pp.1165~1171 (1990)
  3. Touw DJ, "Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus", Pharm World Sci, 23, pp.200~208 (2001)
  4. Nielsen EI, "Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study", Clin Pharmacokinet, 48, pp.253~259 (2009)
  5. Seaton C, "Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition", Antimicrob Chemother, 59, pp.681~690 (2007)
  6. García B, "Population pharmacokinetics of gentamicin in premature newborns", J Antimicrob Chemother, 58, pp.372~381 (2006)
  7. Xuan D, "Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing", Int J Antimicrob Agents, 23, pp.291~298 (2004)
  8. Tréluyer JM, "Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children", Antimicrob Agents Chemother, 46, pp.1381~1388 (2002)
  9. Biggeri A, "Non-parametric maximum likelihood estimators for disease mapping", Stat Med, 15, pp.2539~2546 (2000)
  10. Bustad A, "Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies", Clin Pharmacokinet, 45, pp.365~371 (2006)
  11. Stolk LM, "Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates", Ther Drug Monit, 24, pp.527~533 (2002)
  12. Rougier F, "Aminoglycoside nephrotoxicity: modeling, simulation, and control", Antimicrob Agents Chemother, 47, pp.1010~1018 (2003)
  13. Garrison MW, "Aminoglycosides: another perspective", Ann Pharmacother, 24, pp.267~273 (1990)
  14. Burm JP, "The influence of weight with assay error on gentamicin pharmacokinetics using the Bayesian and nonlinear least square regression analysis in appendicitis patients", Biopharm. Drug Dispos, 26, pp.189~195 (2005)
  15. Jelliffe RW, "The USC*PACK PC programs for planning, monitoring and adjusting drug dosage regimens", Proceedings of the twenty-third annual meeting of the Association for the Advancement of Medical Instrumentation (1988)
  16. Press SJ, "Bayesian statistics: Principles, models, and application", pp.175~ (1989), John Wiley & Sons, Inc
  17. Jelliffe RW, "User manual for the nonparametric EM program for population pharmacokinetic modeling version 1" (1989), University of Southern California, School of Medicine
  18. Sawchuk RJ, "Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients", J Pharmacokinet Biopharm, 4, pp.183~188 (1976)
  19. Vercaigne LM, "Bayesian pharmacokinetics of gentamicin in a haemodialysis population", Clin Pharmacokinet, 43, pp.205~210 (2004)
  20. Jelliffe RW, "Individualizing gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring stategies", Clin Pharmacokinet, 21, pp.461~468 (1991)
  21. Erdmann SM, "An updated comparison of drug dosing methods. Part III: amionglycoside antibiotics", Clin Pharmacokinet, 20, pp.374~379 (1991)
  22. Thomson AH, "Bayesian parameter estimation and population pharmacokinetics", Clin Pharmacokinet, 22, pp.447~467 (1992)
  23. Jelliffe RW, "Nonpharmacokinetic factors affecting aminoglycoside therapeutic precision: A simulation study", Drug Invest, 4, pp.20~27 (1992)
  24. Antal EJ, "An evaluation of population pharmacokinetics in therapeutic trials. Part III: prospective data collection versus retrospective data assembly", Clin Pharmacol Ther, 46, pp.552~558 (1989)
  25. Gan SH, "Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms", J Clin Pharm Ther, 29, pp.455~460 (2004)
  26. Beal S, "Population pharmacokinetic data and parameter estimation based on their first two statistical moments", Drug Metab Rev, 16, pp.173~179 (1984)
  27. Asymptotic properties of optimization estimates for the independent net identically distributed case with application to extended least-squares estimate, "Beal S", University of Califormia, ~ (1984)
  28. Mallet A, "A maximum likelihood estimation method for random coefficient regression models", Biometrika, 73, pp.645~656 (1986)
  29. Mallet A, "Nonparametric maxmum likelihood estimation for population pharmacokinetics with application to cyclosporine", J Pharmacokinet Biopharm, 16, pp.311~318 (1988)
  30. Dodge WF, "Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method", Clin Pharmacol Ther, 50, pp.25~30 (1991)
  31. Bond WS, "Ethnicity and psychotropic drugs", Clin Pharm, 10, pp.467~472 (1991)
  32. Wood A, "Ethnic differences in drug disposition and responsiveness", Clin Pharmacokinet, 20, pp.350~356 (1991)
  33. Jhee SS, "Comparison of aminoglycoside pharmacokinetics in asian hispanic and caucasian patient using population pharmacokinetic methods", Antimicrob Agents Chemother, 38, pp.2073~2078 (1994)
  34. Botha JH, "Population pharmacokinetics of gentamicin in South African newborns", Eur J Clin Pharmacol, 59, pp.755~760 (2003)

관련 논문AI추천

Pharmacokinetics of Once-Daily Amikacin in Korean Adult Patients김혜경, 안보숙, 오정미, 지은희한국임상약학회 · 한국임상약학회지2011 · 제21권 제3호Population Pharmacokinetic Analysis of Piperacillin/ Tazobactam in Korean Patients with Acute Infections권기태, 김성민, 김신우, 김용균, 배인규, 신재국, 이상록, 정진아, 진성준, 최원석, 최향기, 허지안, 대한화학요법학회대한감염학회 · Infection and Chemotherapy2016 · 제48권 제3호위암환자에서 비선형최소자승 회귀분석과 베이시안 분석에 의한 아미카신의 약물동태에 분석오차의 영향범진필, 최준식한국임상약학회 · 한국임상약학회지2008 · 제18권 제1호위암환자에서 비선형 최소자승 회귀분석과 베이시안 분석에 의한 토브라마이신의 약물동태에 분석오차의 영향범진필, 최준식한국임상약학회 · 한국임상약학회지2009 · 제19권 제1호Amikacin Pharmacokinetics and a New Dosing Guideline in Korean Neonates곽혜선, 김재연, 신혜영, 안숙희한국병원약사회 · 병원약사회지2006 · 제23권 제3호Vancomycin 초기 투여 용량 개선 방안김은영, 김정현, 손기호, 유재영, 인용원한국임상약학회 · 한국임상약학회지2010 · 제20권 제3호

이 간행물의 다른 논문 (16건)

담즙산의 생체 활성 물질로서의 역할방준석, 정지훈, 손의동, 이유정pp. 49-56제2형 당뇨병 환자에게 인크레틴 기반 약물치료요법김헌성, 김현아pp. 57-65병원 약사들의 위해약물 안전 수칙의 인지도 및 수행도에 대한 조사연구서인영, 김영주, 이병구pp. 66-73고혈압과 당뇨병 노인의 복약순응도와 이에 영향을 미치는 요인김성옥pp. 81-89정보 성분과 상대위험도를 이용한 clopidogrel의 약물상호작용 시그널 검색 : 건강보험데이터베이스를 대상으로 한 데이터마이닝 연구신완균, 김진형, 손성호, 오정미, 최청암pp. 90-99
원문 보기